PASADENA, Calif. — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical...
Latest News
Boston, Mass. – Sickle cell disease, while rare, is the most common inherited blood disorder and affects over 100,000 people in the United States, more than 90% of whom are Black according to the Centers for Disease Control and Prevention. Although a medication called hydroxyurea can alleviate pain and lower...
Villejuif, France – Aglaia Therapeutics, a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, today announces the successful completion of a €4M ($4.7M) seed funding round. Advent France Biotechnology (AFB) led the round, with the participation of Crédit Mutuel Innovation and Pierre Fabre. AFB also acted...
LOS ANGELES, Calif. — A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable. The study will investigate if chemotherapy followed by a novel type of surgery to remove the cancer is a safe...
London, Ontario – A new study shows oxygenation levels in the placenta, formed during the last three months of fetal development, are an important predictor of cortical growth (development of the outermost layer of the brain or cerebral cortex) and is likely a predictor of childhood cognition and behaviour. “Many...
Lausanne, Switzerland – Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a negative role in cancer immunity – is positively correlated with long-term cancer remission....
Boston, MA – A significant survival improvement for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia is published today by the New England Journal of Medicine. The practice-changing finding is from the randomized phase 3 study E1910 (NCT02003222), which evaluated blinatumomab immunotherapy in patients who were in remission...
London – The effectiveness of live zoster (shingles) vaccine is highest in the first year after vaccination and then wanes substantially. But it continues to provide some protection against shingles and its complications ten years after vaccination, even in patients with a weakened immune system, finds a study published by...
ST. PAUL, Minn. — One in four multiple sclerosis (MS) patients are declining to fill their prescriptions likely due to high out-of-pocket costs, according to new research conducted by pharmacy benefits manager Prime Therapeutics (Prime). The study found that patients with an out-of-pocket expense greater than $250 were seven times...
Salt Lake City, Utah – New research from Intermountain Health in Salt Lake City finds that genetic screening is effective in identifying patients who have a heart condition known as cardiomyopathy to improve their quality of life and reduce deaths. By undergoing genetic screening to identity those with the potentially-fatal...